US-based specialist pharmaceutical company AcelRx has reported positive topline results from its Phase III SAP302 trial of ARX-04 to treat trauma or injury related, moderate-to-severe acute pain.
ARX-04 is developed as a non-invasive, investigational product candidate consisting of 30mcg sufentanil tablets delivered sublingually through a disposable, pre-filled, single-dose applicator (SDA).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase III SAP302 trial was designed as a single-arm, open-label study divided into two cohorts.
The first cohort included 40 adult patients administered with a single dose of ARX-04, while the second cohort included 36 adult patients who were treated with four doses of ARX-04 given on an hourly basis, depending on pain levels.
The interim results of the first cohort were reported in February and recorded a baseline change in the density pain for patients treated with ARX-04.
Results of the second cohort also reported a baseline change in the pain density, in which 75% of the patients experienced pain relief with a single dosage of ARX-04 with 8% of patients requiring to receive morphine in addition to ARX-04.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdditionally, the ARX-04 also predicted the beginning of activity in patients enrolled within SAP302 and was well tolerated during the study.
AcelRx Pharmaceuticals co-founder and chief medical officer Dr Pamela Palmer said: "The Department of Defence has provided us with development funding for ARX-04 and suggested that we conduct a cognitive impairment assessment to determine if ARX-04 causes cognitive deficiencies, which is an understandable concern when treating wounded soldiers on the battlefield.
"In addition to putting combat units in danger, drug-induced cognitive effects can impede diagnosis and treatment in a civilian emergency room.
"If borne out, ARX-04's onset of pain relief, sublingual dosage form and side effect profile could make it an attractive option for doctors considering opioid analgesic treatment in emergency rooms and field-based settings."
The initial Phase III SAP301 ambulatory surgery study of ARX-04 has also exhibited positive results in treating trauma or injury related, moderate-to-severe acute pain.
